ArticleScientific reports2025
A nomogram for predicting cancer-specific survival in patients with rectal mucinous adenocarcinoma following surgery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of prognostic nomograms for patients with cervical cancer and liver metastasis: a SEER-based study.Translational cancer research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nomograms for predicting survival are well-established for colorectal adenocarcinoma but are less common for rectal mucinous adenocarcinoma (MAC). This study leverages Surveillance, Epidemiology, and End Results (SEER) database to develop a prognostic nomogram for rectal MAC, enhancing survival prediction and clinical decision-making. Data from the SEER (2004-2017) were analyzed, focusing on surgically treated rectal MAC patients. The study excluded cases with inadequate follow-up or incomplete data. Demographic and pathological variables, along with treatment modalities (radiotherapy and chemotherapy), were examined. A nomogram was developed to predict 1-, 3-, and 5-year cancer-specific survival (CSS), and its accuracy was validated using receiver operating characteristic (ROC) curves, calibration, and decision curve analysis (DCA). The study included 690 patients, segmented into training (483) and validation (207) cohorts. Significant factors affecting survival included age and cancer stage. The resulting nomogram, incorporating age and TNM stages, demonstrated a concordance index of 0.722 and was further validated through ROC analysis, calibration, and DCA, showing robust predictive performance and clinical utility. Age and TNM staging are critical predictors of CSS in rectal MAC patients post-surgery. The developed nomogram, utilizing these factors, offers improved prognostic accuracy and is a valuable tool for clinical practice, facilitating more informed treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.